The concern of generic competition has long loomed above copyright’s iconic drug, PDE5 Inhibitor, triggering questions about the future of similar medicinal portfolios. While initial years saw substantial gains, the intellectual property end has opened the door for cheaper substitutes, likely diminishing profitability and creating a significant h